[go: up one dir, main page]

PE20140765A1 - Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos - Google Patents

Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos

Info

Publication number
PE20140765A1
PE20140765A1 PE2013002789A PE2013002789A PE20140765A1 PE 20140765 A1 PE20140765 A1 PE 20140765A1 PE 2013002789 A PE2013002789 A PE 2013002789A PE 2013002789 A PE2013002789 A PE 2013002789A PE 20140765 A1 PE20140765 A1 PE 20140765A1
Authority
PE
Peru
Prior art keywords
glutamine
lysine
pharmaceutical composition
leucine
alanine
Prior art date
Application number
PE2013002789A
Other languages
English (en)
Inventor
Sung Youb Jung
Myung Hyun Jang
Ling Ai Shen
Young Kyung Park
Young Jin Park
Se Chang Kwon
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47296599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140765(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of PE20140765A1 publication Critical patent/PE20140765A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN PEPTIDO DERIVADO DE OXINTOMODULINA QUE ACTIVA EL RECEPTOR DE GLP-1 Y EL RECEPTOR DE GLUCAGON QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE FORMULA 1 QUE ES R1-X1-X2-GTFTSD-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-X23-X24-R2, DONDE R1 ES HISTIDINA, DESAMINOHISTIDILO, 4-IMIDAZOACETILO, ENTRE OTROS; X1 ES ACIDO AMINOISOBUTIRICO, GLICINA, ENTRE OTROS; X2 ES ACIDO GLUTAMICO O GLUTAMINA; X3 ES LEUCINA O TIROSINA; X4 ES SERINA O ALANINA; X5 ES LISINA O ARGININA; X6 ES GLUTAMINA O TIROSINA; X7 ES LEUCINA O METIONINA; X8 ES ACIDO ASPARTICO O GLUTAMICO; X9 ES SERINA, ENTRE OTROS; X10 ES GLUTAMINA, LISINA, ENTRE OTROS; X11 ES ALANINA, VALINA, ENTRE OTROS; X12 ES SERINA, VALINA, ENTRE OTROS; X13 ES LISINA, GLUTAMINA, ENTRE OTROS; X14 ES ACIDO ASPARTICO, LEUCINA, ENTRE OTROS; X15 ES FENILALANINA; X16 ES ISOLEUCINA, ENTRE OTROS; X17 ES ALANINA, CISTEINA, ENTRE OTROS; X18 ES TRIPTOFANO; X19 ES ISOLEUCINA, SERINA, ENTRE OTROS; X20 ES LISINA, METIONINA, ENTRE OTROS; X21 ES ASPARAGINA; X22 ES ALANINA, TREONINA, ENTRE OTROS; X23 ES CISTEINA, ENTRE OTROS; X24 ES UN PEPTIDO DE 2 A 10 AMINOACIDOS; R2 ES LA SEQ ID N�: 32, 33, 34, 35, 36, 37 O ESTA SUPRIMIDO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE OBESIDAD
PE2013002789A 2011-06-10 2012-06-07 Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos PE20140765A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20110056472 2011-06-10

Publications (1)

Publication Number Publication Date
PE20140765A1 true PE20140765A1 (es) 2014-06-14

Family

ID=47296599

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2013002789A PE20140765A1 (es) 2011-06-10 2012-06-07 Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
PE2018000633A PE20181299A1 (es) 2011-06-10 2012-06-07 Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
PE2023001927A PE20240686A1 (es) 2011-06-10 2012-06-07 Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2018000633A PE20181299A1 (es) 2011-06-10 2012-06-07 Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
PE2023001927A PE20240686A1 (es) 2011-06-10 2012-06-07 Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)

Country Status (32)

Country Link
US (4) US9527898B2 (es)
EP (3) EP3434687B1 (es)
JP (5) JP6014127B2 (es)
KR (2) KR101502299B1 (es)
CN (1) CN103732618B (es)
AR (1) AR086866A1 (es)
AU (4) AU2012267398B2 (es)
BR (2) BR112013031794B1 (es)
CA (2) CA2838503C (es)
CL (1) CL2013003547A1 (es)
CY (1) CY1120781T1 (es)
DK (3) DK2718318T3 (es)
ES (3) ES2692187T3 (es)
HR (1) HRP20181591T1 (es)
HU (1) HUE040307T2 (es)
IL (3) IL245557B (es)
LT (1) LT2718318T (es)
MX (3) MX350708B (es)
MY (1) MY169309A (es)
PE (3) PE20140765A1 (es)
PH (2) PH12018501954A1 (es)
PL (1) PL2718318T3 (es)
PT (1) PT2718318T (es)
RS (1) RS57711B1 (es)
RU (2) RU2612906C2 (es)
SG (2) SG10201604564XA (es)
SI (1) SI2718318T1 (es)
SM (1) SMT201800649T1 (es)
TW (2) TWI619724B (es)
UA (2) UA126465C2 (es)
WO (1) WO2012169798A2 (es)
ZA (1) ZA201309054B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
UA126465C2 (uk) * 2011-06-10 2022-10-12 Ханмі Сайенс Ко., Лтд. Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
KR101577734B1 (ko) 2011-06-17 2015-12-29 한미사이언스 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
EP2758426B1 (en) 2011-09-23 2019-08-07 Novo Nordisk A/S Novel glucagon analogues
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
TWI652071B (zh) 2012-11-06 2019-03-01 韓美藥品股份有限公司 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑
MA38276B1 (fr) 2012-12-21 2018-03-30 Sanofi Sa Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AR096890A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
AR098614A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Compuesto para el tratamiento de hipoglicemia severa
AR098615A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
MY186251A (en) 2014-01-20 2021-06-30 Hanmi Pharm Ind Co Ltd Long-acting insulin and use thereof
ES2897935T3 (es) 2014-03-31 2022-03-03 Hanmi Pharm Ind Co Ltd Método para mejorar la solubilidad de proteína y péptido mediante el uso del enlace a un fragmento Fc de inmunoglobulina
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) * 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
KR20150140177A (ko) 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
EP3575314B1 (en) * 2014-12-30 2024-02-14 Hanmi Pharm. Co., Ltd. Glucagon derivative
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2017003191A1 (en) 2015-06-30 2017-01-05 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
CR20180380A (es) 2015-12-31 2018-12-07 Hanmi Pharm Ind Co Ltd Agosnista triple de receptores de glucagón/glp-1/gip
KR102574993B1 (ko) * 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
AU2017289014B2 (en) * 2016-06-29 2019-12-05 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
WO2018056764A1 (ko) 2016-09-23 2018-03-29 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
JP2019536823A (ja) 2016-12-05 2019-12-19 ハンミ ファーマシューティカル カンパニー リミテッド 免疫反応が弱化された結合体
CN108299554B (zh) * 2017-01-13 2021-05-25 博瑞生物医药（苏州）股份有限公司 胃泌酸调节素类似物
WO2018143729A1 (ko) 2017-02-03 2018-08-09 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
CN106986924A (zh) * 2017-03-23 2017-07-28 中国药科大学 胃泌酸调节素（oxm）类似物及其应用
JP7604098B2 (ja) 2017-03-23 2024-12-23 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少されたインスリンアナログの結合体及びその用途
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
JP2021530533A (ja) 2018-07-19 2021-11-11 ディーアンドディー ファーマテック インコーポレイテッド ポリペプチドを含む医薬組成物
WO2020019813A1 (zh) * 2018-07-25 2020-01-30 中国药科大学 长效化胃泌酸调节素杂合肽及其制备方法和应用
BR112021006477A2 (pt) * 2018-10-04 2021-07-13 Hanmi Pharm. Co., Ltd. combinação que compreende uma substância com atividade para um receptor de glucagon ou um conjugado do mesmo, kit e composição farmacêutica para prevenir ou tratar doenças
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
WO2020167010A1 (ko) * 2019-02-15 2020-08-20 한미정밀화학주식회사 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
JP2023525260A (ja) * 2020-05-09 2023-06-15 天津薬物研究院有限公司 二重受容体アゴニスト作用を有するポリペプチド誘導体及びその用途
KR20240053545A (ko) * 2022-10-14 2024-04-24 한미약품 주식회사 신규한 glp-1 수용체 길항제 및 이를 포함하는 선천성 고인슐린증 또는 저혈당증의 예방 또는 치료용 약학적 조성물

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1952820A3 (en) 1998-03-06 2012-06-20 Chugai Seiyaku Kabushiki Kaisha Protein-free G-CSF formulations
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (ko) * 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
KR100775343B1 (ko) 2003-11-13 2007-11-08 한미약품 주식회사 면역글로불린 Ｆｃ 영역을 캐리어로 포함하는 약제학적조성물
WO2006059106A2 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
US8404637B2 (en) * 2005-02-11 2013-03-26 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
JP2008543816A (ja) 2005-06-13 2008-12-04 インペリアル イノベーションズ リミテッド 新規化合物および該化合物が摂食行動に及ぼす効果
CN101389648B (zh) 2006-02-22 2013-07-17 默沙东公司 肽胃泌酸调节素衍生物
AU2007258609B2 (en) 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
CA2677932A1 (en) * 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX2010000380A (es) 2007-07-10 2010-03-29 Lilly Co Eli Formulacion de proteina de fusion glp-1-fc.
KR20100058550A (ko) 2007-09-11 2010-06-03 몬도바이오테크 래보래토리즈 아게 녹농균 감염 치료시 치료제로서의 밴드 ３ 단백질 （８２４－８２９） 및／또는 멜라닌세포－자극 호르몬 방출－저해 인자의 용도
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
AU2009260301B2 (en) 2008-06-17 2015-09-03 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
CL2009001424A1 (es) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso.
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
WO2010033220A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010033207A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
CA2747155A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
MX2011006524A (es) 2008-12-19 2011-08-17 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
AU2010226392B9 (en) 2009-03-20 2014-05-22 Amgen Inc. Selective and potent peptide inhibitors of Kv1.3
CA2755395C (en) 2009-03-20 2015-02-24 Hanmi Holdings Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
WO2011056713A2 (en) 2009-11-03 2011-05-12 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for obstructive sleep apnea
WO2011071957A1 (en) 2009-12-07 2011-06-16 Sea Lane Biotechnologies, Llc Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
KR20130018410A (ko) 2010-03-26 2013-02-21 노보 노르디스크 에이/에스 새로운 글루카곤 유사체
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN101974077A (zh) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 一种新颖的多肽化合物
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR101767570B1 (ko) 2010-10-26 2017-08-14 한미사이언스 주식회사 항 비만 펩타이드의 지속형 결합체
CN102010473A (zh) 2010-11-10 2011-04-13 曹鹏 重组胃泌酸调节素融合蛋白及其制备和应用
CN103402536A (zh) 2010-12-22 2013-11-20 马克迪亚生物科技公司 用gip和glp-1受体活性的基于胰高血糖素的肽来治疗代谢异常和肥胖的方法
JP6118500B2 (ja) 2011-02-28 2017-04-19 ローム アンド ハース エレクトロニック マテリアルズ エルエルシーＲｏｈｍ ａｎｄ Ｈａａｓ Ｅｌｅｃｔｒｏｎｉｃ Ｍａｔｅｒｉａｌｓ ＬＬＣ フォトレジスト組成物、およびフォトリソグラフィパターンを形成する方法
KR101161526B1 (ko) 2011-05-16 2012-07-02 숭실대학교산학협력단 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
UA126465C2 (uk) 2011-06-10 2022-10-12 Ханмі Сайенс Ко., Лтд. Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
KR101577734B1 (ko) 2011-06-17 2015-12-29 한미사이언스 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CN104487082A (zh) 2012-04-19 2015-04-01 奥普科生物制品有限公司 长效胃泌酸调节素变体及其生产方法
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
TWI652071B (zh) 2012-11-06 2019-03-01 韓美藥品股份有限公司 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
JP6137046B2 (ja) 2014-05-09 2017-05-31 信越化学工業株式会社 単量体、高分子化合物、レジスト材料及びパターン形成方法

Also Published As

Publication number Publication date
RU2013154066A (ru) 2015-07-20
CN103732618A (zh) 2014-04-16
IL245557A0 (en) 2016-06-30
TWI674271B (zh) 2019-10-11
HRP20181591T1 (hr) 2018-11-30
ZA201309054B (en) 2014-08-27
CA2838503C (en) 2020-02-18
TW201803895A (zh) 2018-02-01
AU2016273908A1 (en) 2017-01-12
DK2718318T3 (en) 2018-11-05
RU2612906C2 (ru) 2017-03-13
KR20120137271A (ko) 2012-12-20
AU2012267398B2 (en) 2016-10-13
ES2875748T3 (es) 2021-11-11
JP6862493B2 (ja) 2021-04-21
EP2718318A4 (en) 2014-12-31
CY1120781T1 (el) 2019-12-11
EP3878859B1 (en) 2023-11-01
CN103732618B (zh) 2018-10-09
AU2018213964A1 (en) 2018-08-23
RU2017105866A3 (es) 2020-06-26
TWI619724B (zh) 2018-04-01
DK3878859T5 (da) 2024-06-10
DK3434687T3 (da) 2021-06-07
US9527898B2 (en) 2016-12-27
JP6312765B2 (ja) 2018-04-18
WO2012169798A3 (en) 2013-02-14
US20170342122A1 (en) 2017-11-30
JP2019189611A (ja) 2019-10-31
IL260582B (en) 2019-09-26
EP3434687A2 (en) 2019-01-30
SG10201604564XA (en) 2016-07-28
US9765131B2 (en) 2017-09-19
US10442848B2 (en) 2019-10-15
AU2012267398A1 (en) 2014-01-16
DK3878859T3 (da) 2024-01-02
RU2017105866A (ru) 2019-01-23
US20140128318A1 (en) 2014-05-08
ES2692187T3 (es) 2018-11-30
SG195258A1 (en) 2013-12-30
MX391293B (es) 2025-03-21
US9522946B2 (en) 2016-12-20
NZ618810A (en) 2016-03-31
EP3434687B1 (en) 2021-03-10
CA2838503A1 (en) 2012-12-13
EP2718318A2 (en) 2014-04-16
JP2017043624A (ja) 2017-03-02
AU2020201322A1 (en) 2020-03-12
SMT201800649T1 (it) 2019-01-11
EP3434687A3 (en) 2019-02-20
EP3878859A1 (en) 2021-09-15
JP2014516566A (ja) 2014-07-17
WO2012169798A2 (en) 2012-12-13
KR101573636B1 (ko) 2015-12-03
UA114710C2 (uk) 2017-07-25
BR122020011001B1 (pt) 2022-09-20
PE20240686A1 (es) 2024-04-10
JP6014127B2 (ja) 2016-10-25
AU2020201322B2 (en) 2021-04-29
PT2718318T (pt) 2018-11-09
JP7094327B2 (ja) 2022-07-01
PH12013502518A1 (en) 2014-01-20
IL245557B (en) 2018-12-31
NZ748012A (en) 2020-01-31
MX2013014468A (es) 2014-05-13
NZ734808A (en) 2018-11-30
PL2718318T3 (pl) 2019-02-28
CA3064214A1 (en) 2012-12-13
MX350708B (es) 2017-09-14
JP2018117629A (ja) 2018-08-02
AR086866A1 (es) 2014-01-29
BR112013031794A2 (pt) 2016-12-20
NZ731342A (en) 2017-09-29
IL268984A (en) 2019-10-31
BR112013031794B1 (pt) 2020-11-10
PH12018501954A1 (en) 2023-02-13
KR20140130659A (ko) 2014-11-11
LT2718318T (lt) 2018-10-25
RS57711B1 (sr) 2018-12-31
JP2020183433A (ja) 2020-11-12
ES2968043T3 (es) 2024-05-06
EP2718318B1 (en) 2018-07-25
UA126465C2 (uk) 2022-10-12
TW201307380A (zh) 2013-02-16
NZ755534A (en) 2020-10-30
AU2018213964B2 (en) 2020-03-19
SI2718318T1 (sl) 2018-11-30
MY169309A (en) 2019-03-21
CA3064214C (en) 2023-03-07
KR101502299B1 (ko) 2015-03-11
IL268984B (en) 2021-04-29
HUE040307T2 (hu) 2019-02-28
US20150291679A1 (en) 2015-10-15
NZ717174A (en) 2017-07-28
RU2739209C2 (ru) 2020-12-21
US20170022261A1 (en) 2017-01-26
AU2016273908B2 (en) 2018-08-23
PE20181299A1 (es) 2018-08-09
CL2013003547A1 (es) 2014-06-27
NZ740049A (en) 2019-05-31
MX2022004041A (es) 2022-08-10

Similar Documents

Publication Publication Date Title
PE20140765A1 (es) Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
PE20190355A1 (es) Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo
PE20180158A1 (es) Coagonistas de los receptores de glucagon y de glp-1
PE20171154A1 (es) Derivados de glucagon con estabilidad mejorada
AR086969A1 (es) Conjugado que comprende oxontomodulina y un fragmento de inmunoglobulina, y su uso
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
PE20180571A1 (es) Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
PE20141551A1 (es) Proteinas de fusion para tratar trastornos metabolicos
IL276294B1 (en) Human cd30 ligand antigen binding proteins
CL2012000119A1 (es) Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus.
EA201270723A1 (ru) Новые пептиды и способы их получения и применения
PE20150648A1 (es) Proteinas de fusion para el tratamiento de un sindrome metabolico
EA201291234A1 (ru) Аналоги глюкагона
PE20110707A1 (es) Variantes de inmunoglobulinas
RU2014133818A (ru) Стабилизированный состав pth
MX2019006260A (es) Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad.
WO2009035540A3 (en) Analogues of exendin-4 and exendin-3
AR087973A1 (es) Variantes del factor 21 del crecimiento de fibroblastos
PE20110106A1 (es) Peptidos mediadores del eflujo del colesterol mejorados
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
PE20140724A1 (es) Coagonistas del receptor de glucagon/glp-1
CL2012001685A1 (es) Análogo peptídico de oxintomodulina, en donde el aminoácido c-terminal es opcionalmente amidado; composición farmacéutica que lo comprende; y su uso en la preparación de un medicamento para el tratamiento de diabetes no insulinodependiente u obesidad.
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
CL2016001405A1 (es) A peptide mixture

Legal Events

Date Code Title Description
FG Grant, registration